IN2014CN03043A - - Google Patents
Info
- Publication number
- IN2014CN03043A IN2014CN03043A IN3043CHN2014A IN2014CN03043A IN 2014CN03043 A IN2014CN03043 A IN 2014CN03043A IN 3043CHN2014 A IN3043CHN2014 A IN 3043CHN2014A IN 2014CN03043 A IN2014CN03043 A IN 2014CN03043A
- Authority
- IN
- India
- Prior art keywords
- derivatives
- compositions
- udp
- those
- disorders
- Prior art date
Links
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 108010026311 purinoceptor P2Y6 Proteins 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541919P | 2011-09-30 | 2011-09-30 | |
| PCT/US2012/058080 WO2013049686A1 (en) | 2011-09-30 | 2012-09-28 | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN03043A true IN2014CN03043A (enExample) | 2015-07-03 |
Family
ID=47996472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3043CHN2014 IN2014CN03043A (enExample) | 2011-09-30 | 2012-09-28 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US8598141B2 (enExample) |
| EP (1) | EP2760858B1 (enExample) |
| JP (1) | JP6162125B2 (enExample) |
| CN (2) | CN103906745B (enExample) |
| AU (1) | AU2012315671B2 (enExample) |
| CA (1) | CA2850367C (enExample) |
| IL (1) | IL231787A (enExample) |
| IN (1) | IN2014CN03043A (enExample) |
| WO (1) | WO2013049686A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6162125B2 (ja) * | 2011-09-30 | 2017-07-12 | タフツ・ユニバーシティ | 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法 |
| US9163055B2 (en) * | 2012-09-28 | 2015-10-20 | Tufts University | Methods for treating glaucoma using uridine diphosphate derivatives |
| PL2968385T3 (pl) * | 2013-03-13 | 2019-05-31 | Univ Tufts | Pochodne nukleozydów urydynowych, kompozycje i sposoby zastosowania |
| US10138265B2 (en) | 2013-03-13 | 2018-11-27 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
| EP3286172B1 (en) | 2015-04-23 | 2019-06-12 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
| EA201792261A1 (ru) | 2015-05-29 | 2018-04-30 | Зе Боард Оф Трастис Оф Зе Лилэнд Стэнфорд Джуниор Юниверсити | Нуклеозидные вещества для уменьшения вредной активности генов, содержащих удлиненные нуклеотидные повторы |
| EP3515447A4 (en) * | 2016-09-26 | 2020-05-27 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
| LT3532459T (lt) | 2016-10-26 | 2023-11-10 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitoriai ir jų medicininis panaudojimas |
| US20220241311A1 (en) * | 2018-06-14 | 2022-08-04 | Mayo Foundation For Medical Education And Research | Methods and materials for treating glycosylation disorders |
| US20230165885A1 (en) * | 2020-03-24 | 2023-06-01 | Gliaguard, Inc. | Treatment of eye disorders with uridine phosphate derivatives |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0621073B2 (ja) | 1986-03-06 | 1994-03-23 | 日水製薬株式会社 | 中枢抑制剤 |
| JP3032053B2 (ja) | 1991-09-06 | 2000-04-10 | 日水製薬株式会社 | ウリジン誘導体及びこれを含有する医薬 |
| US5962459A (en) | 1996-05-28 | 1999-10-05 | Polifarma S.P.A. | Therapeutic active agent for treatment of neuron degenerative diseases |
| BR9811612A (pt) | 1997-08-29 | 2000-08-08 | Univ North Carolina | Uso de 5' -difosfato de uridina e similares para tratamento de doenças pulmonares |
| US8314064B2 (en) * | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
| DK1870103T3 (da) | 1998-07-31 | 2010-01-11 | Massachusetts Inst Technology | Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse |
| US20060069061A1 (en) | 1998-07-31 | 2006-03-30 | Dick Wurtman | Compositions containing uridine and choline, and methods utilizing same |
| US20050203053A1 (en) | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
| US20070004670A1 (en) | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| US8143234B2 (en) | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US20050074819A1 (en) * | 2003-10-01 | 2005-04-07 | Japan Health Sciences Foundation | Screening method of drug for treatment of neuropathic pain |
| WO2005122767A1 (en) | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
| US7851456B2 (en) | 2005-06-29 | 2010-12-14 | Inspire Pharmaceuticals, Inc. | P2Y6 receptor agonists for treating lung diseases |
| JP5513135B2 (ja) | 2007-03-19 | 2014-06-04 | カスケード プロドラッグ インコーポレイテッド | マンニッヒ塩基ｎ−オキシド薬物 |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| WO2010039548A2 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| EP2646449B1 (en) | 2010-12-01 | 2015-08-19 | Bar-Ilan University | Uridine di- or tri-phosphate derivatives and uses thereof |
| JP6162125B2 (ja) * | 2011-09-30 | 2017-07-12 | タフツ・ユニバーシティ | 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法 |
| US9163055B2 (en) * | 2012-09-28 | 2015-10-20 | Tufts University | Methods for treating glaucoma using uridine diphosphate derivatives |
| US10138265B2 (en) | 2013-03-13 | 2018-11-27 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
| PL2968385T3 (pl) * | 2013-03-13 | 2019-05-31 | Univ Tufts | Pochodne nukleozydów urydynowych, kompozycje i sposoby zastosowania |
-
2012
- 2012-09-28 JP JP2014533430A patent/JP6162125B2/ja not_active Expired - Fee Related
- 2012-09-28 WO PCT/US2012/058080 patent/WO2013049686A1/en not_active Ceased
- 2012-09-28 IN IN3043CHN2014 patent/IN2014CN03043A/en unknown
- 2012-09-28 CN CN201280053228.6A patent/CN103906745B/zh not_active Expired - Fee Related
- 2012-09-28 AU AU2012315671A patent/AU2012315671B2/en not_active Ceased
- 2012-09-28 CN CN201710598982.2A patent/CN107353316B/zh not_active Expired - Fee Related
- 2012-09-28 CA CA2850367A patent/CA2850367C/en not_active Expired - Fee Related
- 2012-09-28 EP EP12837369.3A patent/EP2760858B1/en active Active
-
2013
- 2013-03-08 US US13/791,447 patent/US8598141B2/en not_active Expired - Fee Related
- 2013-11-06 US US14/073,476 patent/US8785620B2/en active Active
-
2014
- 2014-03-27 IL IL231787A patent/IL231787A/en active IP Right Grant
- 2014-07-03 US US14/323,690 patent/US9227993B2/en not_active Expired - Fee Related
-
2016
- 2016-01-04 US US14/987,554 patent/US20160318968A1/en not_active Abandoned
-
2018
- 2018-12-03 US US16/208,481 patent/US11072627B2/en not_active Expired - Fee Related
-
2021
- 2021-07-26 US US17/385,894 patent/US20210347807A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190309009A1 (en) | 2019-10-10 |
| US20160318968A1 (en) | 2016-11-03 |
| CN107353316A (zh) | 2017-11-17 |
| US20210347807A1 (en) | 2021-11-11 |
| CN107353316B (zh) | 2020-08-18 |
| CN103906745A (zh) | 2014-07-02 |
| IL231787A0 (en) | 2014-05-28 |
| US20150045319A1 (en) | 2015-02-12 |
| US8598141B2 (en) | 2013-12-03 |
| US11072627B2 (en) | 2021-07-27 |
| JP6162125B2 (ja) | 2017-07-12 |
| JP2014528418A (ja) | 2014-10-27 |
| EP2760858A4 (en) | 2015-04-22 |
| AU2012315671A1 (en) | 2014-04-17 |
| CN103906745B (zh) | 2017-08-25 |
| IL231787A (en) | 2017-05-29 |
| WO2013049686A1 (en) | 2013-04-04 |
| US8785620B2 (en) | 2014-07-22 |
| EP2760858A1 (en) | 2014-08-06 |
| AU2012315671B2 (en) | 2017-07-20 |
| US20130252919A1 (en) | 2013-09-26 |
| US20140066613A1 (en) | 2014-03-06 |
| EP2760858B1 (en) | 2018-08-08 |
| CA2850367C (en) | 2021-06-01 |
| US9227993B2 (en) | 2016-01-05 |
| CA2850367A1 (en) | 2013-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202202711B (en) | Sustained-release dosage forms of ruxolitinib | |
| EA034135B9 (ru) | Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов | |
| CA2850367C (en) | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders | |
| NZ700928A (en) | Dna-pk inhibitors | |
| IN2014DN09134A (enExample) | ||
| MX2009008531A (es) | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. | |
| NZ710034A (en) | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| MX2014000779A (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide. | |
| GB2511685A (en) | Muscarinic m1 receptor agonists | |
| MY182558A (en) | 1,2,4-triazine derivatives for the treatment of viral infections | |
| IN2014MN02056A (enExample) | ||
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| IN2014MN01982A (enExample) | ||
| NZ630830A (en) | Benzamides | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| MX2015000618A (es) | Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas. | |
| IN2015DN00345A (enExample) | ||
| MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| WO2014082738A8 (en) | Heteroquinoline-3-carboxamides as kcnq2/3 modulators | |
| MX2014000963A (es) | Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide. | |
| IN2014DN08443A (enExample) | ||
| MX2013002119A (es) | Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3. | |
| IN2014KN00849A (enExample) | ||
| MX2014003584A (es) | Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides. |